 |
52 Diseases |  |
1 Trial |
|
1 Trial |  |
293 News |  |
| «12345» |
- | luminespib (AUY922) / Ligand
Trial termination: An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations (clinicaltrials.gov) - Jul 24, 2019
P2, N=59, Terminated, Sponsor: Novartis Pharmaceuticals
Completed --> Terminated; An interim analysis was conducted in May-2014. Upon review of the data, the committee recommended study termination due to futility.
- | luminespib (AUY922) / Ligand
Journal: Evidence for interaction between Hsp90 and the ER membrane complex. (Pubmed Central) - May 24, 2019
Yeast with multiple EMC gene deletions exhibit increased sensitivity to Hsp90 inhibitor as well as defective folding of the well-established Hsp90 folding client, the glucocorticoid receptor. Altogether, our evidence of physical, genetic, and functional interaction of Hsp90 with the EMC, as well as bioinformatic analysis of shared interactors, supports that there is a legitimate interaction between them in vivo.
- | luminespib (AUY922) / Ligand
Biomarker, Clinical, Journal: Identification of novel response and predictive biomarkers to Hsp90 inhibitors through mass spectrometry-based proteomic profiling of patient-derived prostate tumor explants. (Pubmed Central) - Apr 30, 2019
...Independent discovery and validation cohorts of PDEs (n = 16 and 30, respectively) were cultured in the absence or presence of Hsp90 inhibitors AUY922 or 17-AAG...This selective regulation of DNAJA1 was validated by western blot analysis. Our study establishes 'proof-of-principle' that proteomic profiling of drug-treated PDEs represents an effective and clinically-relevant strategy for identification of biomarkers that associate with certain tumor-specific responses.
- | luminespib (AUY922) / Ligand
Trial completion, Trial completion date, Trial primary completion date, Metastases: Pemetrexed Disodium and Hsp90 Inhibitor AUY922 in Treating Patients With Previously Treated Stage IV Non-Small Cell Lung Cancer (clinicaltrials.gov) - Apr 23, 2019
P1, N=13, Completed, Sponsor: Jonsson Comprehensive Cancer Center
Our study establishes 'proof-of-principle' that proteomic profiling of drug-treated PDEs represents an effective and clinically-relevant strategy for identification of biomarkers that associate with certain tumor-specific responses. Active, not recruiting --> Completed | Trial completion date: Jan 2020 --> Oct 2018 | Trial primary completion date: Jan 2019 --> Oct 2018
- | luminespib (AUY922) / Ligand
Biomarker, Clinical, P2 data, Journal: Brief Report: Phase 2 Study of the HSP-90 inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non-Small Cell Lung Cancer. (Pubmed Central) - Apr 5, 2019
Active, not recruiting --> Completed | Trial completion date: Jan 2020 --> Oct 2018 | Trial primary completion date: Jan 2019 --> Oct 2018 AUY922 is active in patients with NSCLC, particularly among patients with ALK rearrangements and EGFR mutations.
- | luminespib (AUY922) / Ligand, Herceptin (trastuzumab) / Roche
Preclinical, Journal: The HSP90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cells. (Pubmed Central) - Mar 29, 2019
NVP-AUY922 in combination with trastuzumab, significantly enhanced growth inhibition in three of the seven cell lines tested. In conclusion, our data shows that NVP-AUY922 displays potent anti-cancer activity in HER2-positive and trastuzumab-resistant breast cancer cells, and supports further testing of NVP-AUY922 in patients with HER2-positive breast cancer.
- | luminespib (AUY922) / Ligand
Trial completion: Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (clinicaltrials.gov) - Dec 14, 2018
P1/2, N=38, Completed, Sponsor: Northwestern University
In conclusion, our data shows that NVP-AUY922 displays potent anti-cancer activity in HER2-positive and trastuzumab-resistant breast cancer cells, and supports further testing of NVP-AUY922 in patients with HER2-positive breast cancer. Active, not recruiting --> Completed
- | Journal: Proteomic analysis of proteome and histone post-translational modifications in heat shock protein 90 inhibition-mediated bladder cancer therapeutics. (Pubmed Central) - Sep 7, 2018
Furthermore, quantitative proteome studies identified 14 types of PTMs with 93 marks on the core histones, including 34 novel histone marks of butyrylation, citrullination, 2-hydroxyisobutyrylation, methylation, O-GlcNAcylation, propionylation, and succinylation in AUY922- and ganetespib-treated 5637 cells. Together, this study outlines the association between proteomic changes and histone PTMs in response to HSP90 inhibitor treatment in bladder carcinoma cells, and thus intensifies the understanding of HSP90 inhibition-mediated bladder cancer therapeutics.
- | Piqray (alpelisib) / Novartis, Zykadia (ceritinib) / Novartis, Tabrecta (capmatinib) / Incyte, Novartis
Trial completion date, Trial primary completion date, Metastases: A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov) - Jul 11, 2018
P2, N=67, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Together, this study outlines the association between proteomic changes and histone PTMs in response to HSP90 inhibitor treatment in bladder carcinoma cells, and thus intensifies the understanding of HSP90 inhibition-mediated bladder cancer therapeutics. Trial completion date: Aug 2018 --> Feb 2019 | Trial primary completion date: Aug 2018 --> Feb 2019
- || Piqray (alpelisib) / Novartis, Zykadia (ceritinib) / Novartis, Tabrecta (capmatinib) / Incyte, Novartis
Trial completion date, Trial primary completion date, Metastases: A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov) - May 1, 2018
P2, N=67, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Aug 2018 --> Feb 2019 | Trial primary completion date: Aug 2018 --> Feb 2019 Trial completion date: Apr 2018 --> Aug 2018 | Trial primary completion date: Apr 2018 --> Aug 2018
- | luminespib (AUY922) / Ligand
Trial completion date, Trial primary completion date, Metastases: Pemetrexed Disodium and Hsp90 Inhibitor AUY922 in Treating Patients With Previously Treated Stage IV Non-Small Cell Lung Cancer (clinicaltrials.gov) - Apr 30, 2018
P1, N=13, Active, not recruiting, Sponsor: Jonsson Comprehensive Cancer Center
Trial completion date: Apr 2018 --> Aug 2018 | Trial primary completion date: Apr 2018 --> Aug 2018 Trial completion date: Jan 2019 --> Jan 2020 | Trial primary completion date: Jan 2018 --> Jan 2019
- | luminespib (AUY922) / Ligand
Trial completion, Metastases: AUY922 for Advanced ALK-positive NSCLC (clinicaltrials.gov) - Mar 30, 2018
P2, N=6, Completed, Sponsor: Massachusetts General Hospital
Trial completion date: Jan 2019 --> Jan 2020 | Trial primary completion date: Jan 2018 --> Jan 2019 Active, not recruiting --> Completed
- | luminespib (AUY922) / Ligand
Trial primary completion date: Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jan 11, 2018
P1/2, N=43, Active, not recruiting, Sponsor: Northwestern University
Active, not recruiting --> Completed Trial primary completion date: Dec 2017 --> Dec 2019
- | luminespib (AUY922) / Ligand
Trial completion, Enrollment change, Trial primary completion date, Metastases: AUY922 in Patient With Stage IV NSCLC (clinicaltrials.gov) - Dec 30, 2017
P2, N=31, Completed, Sponsor: National Taiwan University Hospital
Trial primary completion date: Dec 2017 --> Dec 2019 Active, not recruiting --> Completed | N=63 --> 31 | Trial primary completion date: Jul 2017 --> Feb 2017
- | luminespib (AUY922) / Ligand, GSK2816126 / GSK
Journal: Hsp90 inhibition destabilizes Ezh2 protein in alloreactive T cells and reduces graft-versus-host disease in mice. (Pubmed Central) - Sep 13, 2017
In contrast, destabilizing T-cell Ezh2 protein by inhibiting Hsp90 using its specific inhibitor AUY922 reduced GVHD in mice undergoing allogeneic HSCT...Importantly, pharmacological inhibition of Hsp90 preserved anti-leukemia activity of donor T cells, leading to improved overall survival of recipient mice after allogeneic HSCT. Our findings identify the Ezh2-Hsp90 interaction as a previously unrecognized mechanism essential for T cell responses and an effective target for controlling GVHD.
- ||| Piqray (alpelisib) / Novartis, Zykadia (ceritinib) / Novartis, Tabrecta (capmatinib) / Incyte, Novartis
Enrollment closed, Enrollment change, Metastases: A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov) - Aug 18, 2017
P2, N=62, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Our findings identify the Ezh2-Hsp90 interaction as a previously unrecognized mechanism essential for T cell responses and an effective target for controlling GVHD. Recruiting --> Active, not recruiting | N=85 --> 62
- | luminespib (AUY922) / Ligand
Journal: Preclinical Study of AUY922, a Novel Hsp90 Inhibitor, in the Treatment of Esophageal Adenocarcinoma. (Pubmed Central) - Jun 2, 2017
Recruiting --> Active, not recruiting | N=85 --> 62 AUY922 exhibits antitumor efficacy in vitro and in vivo for EAC, suggesting the need for human clinical trials.
- | luminespib (AUY922) / Ligand
Enrollment change, Trial primary completion date, Metastases: AUY922 for Advanced ALK-positive NSCLC (clinicaltrials.gov) - Apr 14, 2017
P2, N=6, Active, not recruiting, Sponsor: Massachusetts General Hospital
AUY922 exhibits antitumor efficacy in vitro and in vivo for EAC, suggesting the need for human clinical trials. N=20 --> 6 | Trial primary completion date: Nov 2016 --> Jun 2017
- | luminespib (AUY922) / Ligand
Trial completion, EGFR exon 20: Phase 2 Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR (clinicaltrials.gov) - Mar 14, 2017
P2, N=30, Completed, Sponsor: Massachusetts General Hospital
N=20 --> 6 | Trial primary completion date: Nov 2016 --> Jun 2017 Active, not recruiting --> Completed
- luminespib (AUY922) / Ligand
Enrollment closed, Trial primary completion date, Metastases: AUY922 in Patient With Stage IV NSCLC (clinicaltrials.gov) - Feb 11, 2017
P2, N=63, Active, not recruiting, Sponsor: National Taiwan University Hospital
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2016 --> Jul 2017
- | imatinib / Generic mfg., luminespib (AUY922) / Ligand, Sutent (sunitinib) / Pfizer
Journal: A Phase 2 Study of the Hsp90 Inhibitor AUY922 as Treatment for Patients with Refractory Gastrointestinal Stromal Tumors. (Pubmed Central) - Feb 7, 2017
AUY922 produced a median PFS which compares favorably to historical controls of placebo (6 weeks) for patients refractory to treatment with imatinib. While diarrhea and ocular toxicities were common, the majority of patients received treatment until disease progression.
- luminespib (AUY922) / Ligand
Enrollment closed, EGFR exon 20: Phase 2 Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR (clinicaltrials.gov) - Jan 30, 2017
P2, N=29, Active, not recruiting, Sponsor: Massachusetts General Hospital
While diarrhea and ocular toxicities were common, the majority of patients received treatment until disease progression. Recruiting --> Active, not recruiting
- luminespib (AUY922) / Ligand
Trial primary completion date, Metastases: Pemetrexed Disodium and Hsp90 Inhibitor AUY922 in Treating Patients With Previously Treated Stage IV Non-Small Cell Lung Cancer (clinicaltrials.gov) - Nov 9, 2016
P1, N=13, Active, not recruiting, Sponsor: Jonsson Comprehensive Cancer Center
Recruiting --> Active, not recruiting Trial primary completion date: Aug 2016 --> Jan 2018
- luminespib (AUY922) / Ligand
Trial primary completion date, EGFR exon 20: Phase 2 Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR (clinicaltrials.gov) - Sep 26, 2016
P2, N=29, Recruiting, Sponsor: Massachusetts General Hospital
Trial primary completion date: Aug 2016 --> Jan 2018 Trial primary completion date: Mar 2016 --> Feb 2017
- luminespib (AUY922) / Ligand
Trial primary completion date, Metastases: AUY922 for Advanced ALK-positive NSCLC (clinicaltrials.gov) - Sep 15, 2016
P2, N=20, Active, not recruiting, Sponsor: Massachusetts General Hospital
Trial primary completion date: Mar 2016 --> Feb 2017 Trial primary completion date: Jan 2016 --> Nov 2016
- || Piqray (alpelisib) / Novartis, Zykadia (ceritinib) / Novartis, Tabrecta (capmatinib) / Incyte, Novartis
Trial primary completion date, Metastases: A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov) - Aug 8, 2016
P2, N=85, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Jan 2016 --> Nov 2016 Trial primary completion date: Dec 2017 --> Apr 2018
- luminespib (AUY922) / Ligand
Trial primary completion date, Metastases: AUY922 in Patient With Stage IV NSCLC (clinicaltrials.gov) - Jul 23, 2016
P2, N=63, Recruiting, Sponsor: National Taiwan University Hospital
Trial primary completion date: Dec 2017 --> Apr 2018 Trial primary completion date: Aug 2016 --> Dec 2016
- luminespib (AUY922) / Ligand
Trial primary completion date: Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jul 1, 2016
P1/2, N=43, Active, not recruiting, Sponsor: Northwestern University
Trial primary completion date: Aug 2016 --> Dec 2016 Trial primary completion date: Dec 2016 --> Dec 2017
- | Zykadia (ceritinib) / Novartis
Trial completion, Trial primary completion date: Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer (clinicaltrials.gov) - Jun 10, 2016
P1, N=22, Completed, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Dec 2016 --> Dec 2017 Active, not recruiting --> Completed | Trial primary completion date: Mar 2017 --> Jan 2016
- |||| luminespib (AUY922) / Ligand
Trial completion, Enrollment change, Metastases: Phase II Trial of AUY922 vs. Comparators in Advanced Gastric Cancer (clinicaltrials.gov) - May 3, 2016
P2, N=68, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed | Trial primary completion date: Mar 2017 --> Jan 2016 Terminated --> Completed | N=98 --> 68
- || Piqray (alpelisib) / Novartis, Zykadia (ceritinib) / Novartis, Tabrecta (capmatinib) / Incyte, Novartis
Trial primary completion date, Metastases: A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov) - Apr 22, 2016
P2, N=85, Recruiting, Sponsor: Novartis Pharmaceuticals
Terminated --> Completed | N=98 --> 68 Trial primary completion date: Jun 2017 --> Dec 2017
- luminespib (AUY922) / Ligand
Enrollment closed, Enrollment change, Trial primary completion date, Metastases: Pemetrexed Disodium and Hsp90 Inhibitor AUY922 in Treating Patients With Previously Treated Stage IV Non-Small Cell Lung Cancer (clinicaltrials.gov) - Mar 8, 2016
P1, N=13, Active, not recruiting, Sponsor: Jonsson Comprehensive Cancer Center
Trial primary completion date: Jun 2017 --> Dec 2017 Recruiting --> Active, not recruiting | N=38 --> 13 | Trial primary completion date: Mar 2016 --> Aug 2016
- Zykadia (ceritinib) / Novartis
Trial primary completion date: Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer (clinicaltrials.gov) - Jan 17, 2016
P1, N=22, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting | N=38 --> 13 | Trial primary completion date: Mar 2016 --> Aug 2016 Trial primary completion date: Nov 2015 --> Mar 2017
- |||| luminespib (AUY922) / Ligand
Trial completion: An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations (clinicaltrials.gov) - Dec 17, 2015
P2, N=56, Completed, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Nov 2015 --> Mar 2017 Active, not recruiting --> Completed
- | luminespib (AUY922) / Ligand
Trial completion, Enrollment change, Trial primary completion date: A Study of the HSP90 Inhibitor AUY922 (clinicaltrials.gov) - Dec 16, 2015
P2, N=26, Completed, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=42 --> 26 | Trial primary completion date: Aug 2017 --> Nov 2015
- Zykadia (ceritinib) / Novartis
Trial primary completion date: Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer (clinicaltrials.gov) - Oct 22, 2015
P1, N=22, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed | N=42 --> 26 | Trial primary completion date: Aug 2017 --> Nov 2015 Trial primary completion date: Jul 2015 --> Nov 2015
- ||| Piqray (alpelisib) / Novartis, Zykadia (ceritinib) / Novartis, Tabrecta (capmatinib) / Incyte, Novartis
Enrollment change, Trial primary completion date, Metastases: A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov) - Oct 22, 2015
P2, N=85, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Jul 2015 --> Nov 2015 N=115 --> 85 | Trial primary completion date: Oct 2017 --> Jun 2017
- luminespib (AUY922) / Ligand
Trial primary completion date: HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ET (clinicaltrials.gov) - Sep 24, 2015
P2, N=7, Terminated, Sponsor: Memorial Sloan Kettering Cancer Center
N=115 --> 85 | Trial primary completion date: Oct 2017 --> Jun 2017 Trial primary completion date: Aug 2015 --> May 2015
- luminespib (AUY922) / Ligand
Enrollment closed, Trial primary completion date, Metastases: AUY922 for Advanced ALK-positive NSCLC (clinicaltrials.gov) - Sep 4, 2015
P2, N=20, Active, not recruiting, Sponsor: Massachusetts General Hospital
Trial primary completion date: Aug 2015 --> May 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2015 --> Jan 2016
- | luminespib (AUY922) / Ligand
Trial completion, Trial primary completion date, Stroma: Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor (clinicaltrials.gov) - Aug 12, 2015
P2, N=24, Completed, Sponsor: SCRI Development Innovations, LLC
Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2015 --> Jan 2016 Active, not recruiting --> Completed | Trial primary completion date: Jan 2016 --> Feb 2015
- luminespib (AUY922) / Ligand
Trial primary completion date: A Study of the HSP90 Inhibitor AUY922 (clinicaltrials.gov) - Jun 26, 2015
P2, N=42, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed | Trial primary completion date: Jan 2016 --> Feb 2015 Trial primary completion date: Aug 2016 --> Aug 2017
- luminespib (AUY922) / Ligand
Trial primary completion date: Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jun 25, 2015
P1/2, N=43, Active, not recruiting, Sponsor: Northwestern University
Trial primary completion date: Aug 2016 --> Aug 2017 Trial primary completion date: Dec 2015 --> Dec 2016
- | luminespib (AUY922) / Ligand
P1 data, Enrollment change, Combination therapy: A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma. (clinicaltrials.gov) - Jun 25, 2015
P1/2, N=29, Completed, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Dec 2015 --> Dec 2016 N=38 --> 29
- luminespib (AUY922) / Ligand
Enrollment change, Trial termination: HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ET (clinicaltrials.gov) - Jun 11, 2015
P2, N=7, Terminated, Sponsor: Memorial Sloan Kettering Cancer Center
N=38 --> 29 N=25 --> 7 | Active, not recruiting --> Terminated; patient safety
- | luminespib (AUY922) / Ligand, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Trial primary completion date, Metastases: Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer (clinicaltrials.gov) - Jun 6, 2015
P1, N=20, Completed, Sponsor: Swedish Medical Center
N=25 --> 7 | Active, not recruiting --> Terminated; patient safety Active, not recruiting --> Completed | Trial primary completion date: Jan 2015 --> May 2015
- Zykadia (ceritinib) / Novartis
Enrollment closed, Enrollment change, Trial primary completion date: Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer (clinicaltrials.gov) - Apr 28, 2015
P1, N=22, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed | Trial primary completion date: Jan 2015 --> May 2015 Recruiting --> Active, not recruiting | N=69 --> 22 | Trial primary completion date: Aug 2016 --> Jul 2015
- |||| luminespib (AUY922) / Ligand
Trial completion, Trial primary completion date, Metastases: A Study of AUY922 in Non-small-cell Lung Cancer Patients Who Have Received Previous Two Lines of Chemotherapy. (clinicaltrials.gov) - Apr 20, 2015
P2, N=152, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting | N=69 --> 22 | Trial primary completion date: Aug 2016 --> Jul 2015 Active, not recruiting --> Completed | Trial primary completion date: Nov 2014 --> Aug 2014
- |||| Piqray (alpelisib) / Novartis, Zykadia (ceritinib) / Novartis, Tabrecta (capmatinib) / Incyte, Novartis
Enrollment open, Metastases: A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov) - Mar 12, 2015
P2, N=115, Recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed | Trial primary completion date: Nov 2014 --> Aug 2014 Not yet recruiting --> Recruiting
- | luminespib (AUY922) / Ligand
Enrollment change, Stroma: Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor (clinicaltrials.gov) - Mar 7, 2015
P2, N=24, Active, not recruiting, Sponsor: SCRI Development Innovations, LLC
Not yet recruiting --> Recruiting N=34 --> 24
- luminespib (AUY922) / Ligand, Sutent (sunitinib) / Pfizer
Trial primary completion date, Stroma, Metastases: A Study of AUY922 for GIST(Gastrointestinal Stromal Tumor) Patients (clinicaltrials.gov) - Feb 26, 2015
P2, N=25, Recruiting, Sponsor: National Health Research Institutes, Taiwan
N=34 --> 24 Trial primary completion date: Oct 2014 --> May 2015